#1COPYRIGHT © ABCELLERA Q3 2022 BUSINESS UPDATE NOVEMBER 8, 2022 AbCellera#2Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3Q3 2022 BUSINESS UPDATE M 4 2 2 4 4 4 long live plasma cell Q3 2022. BUSINESS UPDATE SUMMARY. 10 YEARS AT THE CUTTING EDGE OF ANTIBODY DISCOVERY $868M 164 92 7 in cash, cash equivalents & marketable securities cumulative programs under contract cumulative programs started molecules in the clinic#4Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 4 CREATE VALUE BY POWERING INNOVATION. CAPTURE VALUE THROUGH SHARED SUCCESS. PARTNER-INITIATED PROGRAMS Discovery Programs Co-Development Programs TECHNOLOGY-DEVELOPMENT Pre-Partnered Programs#5Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5 сл PARTNERSHIPS 2 DISCOVERY PROGRAMS ADVANCE INTO PRECLINICAL AND CLINICAL DEVELOPMENT REGENERON FIRST candidate to advance into further preclinical development GPCR target 4 targets multi-year multiple indications undisclosed 1 MOLECULE ENTERED THE CLINIC Alzheimer's Disease#6Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6 PRE-PARTNERED PROGRAMS. CREATING VALUE THROUGH TECHNOLOGY-DEVELOPMENT. UNRIVALED ABILITY TO BREAK THE BARRIERS OF CONVENTIONAL DRUG DISCOVERY. T-Cell Engager Platform Hundreds of diverse CD3-binding antibodies to combine to create optimized precision cancer therapies. Clinically-validated OrthoMab™ bispecifics platform, to pair CD3-targeting and tumor-targeting antibodies. Internal validation of panel through work on three well-recognized and high-value targets. GPCRs & lon Channels Platform Clinically validated, membrane-protein targets with large commercial potential that have proven largely intractable using traditional methods for antibody discovery. Internal platform integrated across the best of modern data science and biotechnology to generate best-in-class candidates.#7o COPYRIGHT © ABCELLERA Q3 2022 FINANCIALS UPDATE#8FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 Strong portfolio growth. Total # of Programs Under Contract 164 Total # of Discovery Partners 38 Cumulative # of Program Starts 100 90 80 70 60 50 40 30 20 10 0 92 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q3 WITHOUT downstream participation + WITH downstream participation 7 6 5 4 3 2 1 O Cumulative # of Molecules in the Clinic 7 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q3 Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results.#9FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 Now 7 molecules in the clinic. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) NEW undisclosed NBL-012 NBL-015 undisclosed IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase 1 Phase 1 IND/CTA authorized IND/CTA authorized Clinical field study PARTNER Lilly Lilly undisclosed NovaRock BOTHERAPEUTICS NovaRock BOTHERAPEUTICS undisclosed Invetx™ THERAPEUTIC AREA ● ● ● ● ● ● infectious disease - COVID-19 infectious disease - COVID-19 neurology - Alzheimer's Disease dermatology gastrointestinal disease immunology oncology undisclosed animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership As of September 30, 2022#10FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 $101.4M total revenue, driven by royalties for bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $5.5M $5.1M Q3 2021 $101.4M $93.3M $7.5M Q3 2022#11FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 11 Operating expenses reflect ongoing investments. Operating Expenses USD RESEARCH & DEVELOPMENT $17.5M Q3 2021 +$9.1M ↓ $26.6M Q3 2022 SALES & MARKETING $1.2M Q3 2021 +$1.9M $3.1M Q3 2022 GENERAL & ADMIN $11.3M Q3 2021 +$2.5M $13.8M Q3 2022#12FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 12 Net earnings of $26.6M: equivalent to $0.09 (basic) and $0.08 (diluted) per share. Earnings USD NET EARNINGS -$21.4M Q3 2021 $26.6M Q3 2022 EARNINGS PER SHARE: BASIC -$0.08 2021 Q3 $0.09 2022 Q3 EARNINGS PER SHARE: DILUTED -$0.08 2021 Q3 $0.08 2022 Q3#13FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 13 Nearly 900 million in total cash, equivalents, and marketable securities. Cash Flows USD $748M $247M Marketable Securities $476M Cash & Equivalents $25M* 31-Dec-21 $246M OPERATING $252M Marketable Securities (net) $83M Other ($336M) INVESTING [$2M) FINANCING ($10M) FX $896M $496M Marketable Securities $372M Cash & Equivalents $28M* 30-Sep-22 Restricted cash (including restricted cash in other assets)#1414 COPYRIGHT © ABCELLERA A Q3 2022 BUSINESS UPDATE YOU THANK